How do controlled substance rules affect online ADHD prescriptions?

The rules governing online ADHD prescriptions, especially for stimulant medications (which are controlled substances), have been a rollercoaster since the COVID-19 pandemic. Here's a breakdown of how controlled substance rules affect them:

Key Federal Law: The Ryan Haight Act

At the federal level, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation before a controlled substance can be prescribed via telemedicine. This was designed to prevent "pill mills" and ensure proper medical oversight.

The COVID-19 Public Health Emergency (PHE) Waiver

• What happened: When the COVID-19 pandemic hit, the DEA (Drug Enforcement Administration) issued an exception to the Ryan Haight Act. This waiver allowed healthcare providers to prescribe controlled substances via telehealth without an initial in-person medical evaluation.
• Impact: This waiver enabled the rapid growth of telehealth providers specializing in ADHD diagnosis and medication management, making access significantly easier. Companies like Done, Klarity, and Cerebral expanded significantly during this period.

The End of the PHE and Subsequent Extensions

• PHE End: The federal Public Health Emergency officially ended on May 11, 2023.
• DEA Extensions: Recognizing the potential "cliff effect" for millions of patients, the DEA issued temporary extensions:
  • Initial Extension (to November 11, 2023): This allowed all telehealth providers to continue prescribing controlled substances via telehealth, even to new patients, under the same relaxed rules.
  • Second Extension (to December 31, 2024): This is the current rule. It allows providers to continue prescribing controlled substances via telehealth for patients where a telehealth medical evaluation occurred on or before November 11, 2023.
    • For new patients after November 11, 2023, the in-person requirement generally returned, meaning an initial in-person visit is needed before controlled substances can be prescribed via telehealth. However, there are nuances and ongoing discussions.

The Current State and What It Means for You

1. Existing Patients (Established during PHE): If you started receiving controlled substance prescriptions for ADHD via telehealth from a provider before November 11, 2023, you can likely continue receiving those prescriptions from that same provider via telehealth until at least December 31, 2024. This provides a transition period.

   • Companies like Done, Klarity: For their existing patients, they are generally continuing care under this extension.

2. New Patients Seeking Controlled Substances (Stimulants):

   • In-person requirement is generally back: If you are a new patient seeking a stimulant medication for ADHD, most online-only telehealth providers will now require an initial in-person visit or refer you to an in-person provider for your first assessment and prescription.
   • Hybrid models emerging: Some providers and services are moving towards hybrid models where the initial diagnosis and prescription happen in person, but follow-up appointments and refills can be done via telehealth.
   • Less impacted for non-controlled medications: If you are prescribed non-stimulant ADHD medications (e.g., Strattera, Qelbree, Intuniv), these are not controlled substances, and thus, the telehealth prescribing rules are generally much less restrictive.

Specific Brands and Services:

• Done & Klarity: These services gained popularity during the PHE for their fully online model. They are now navigating the new rules, primarily serving their existing patient base for controlled substances and adapting their intake processes for new patients (e.g., requiring an in-person component or focusing on non-controlled options).
• Cerebral: Another large telehealth platform that faced scrutiny. They, too, are adjusting their policies in line with the evolving regulations, often requiring initial in-person visits for controlled substances.
• Local Telehealth Providers/Hybrid Models: Many traditional psychiatric practices and larger healthcare systems are increasingly offering telehealth. These models often involve an initial in-person visit, with subsequent visits done remotely. This allows them to comply with the Ryan Haight Act while still offering convenience. This could be a good option as it integrates you into a local care system.
• General Telehealth Platforms (e.g., Amwell, Teladoc, MDLIVE): These platforms often connect you with providers who may be able to offer a diagnosis and prescribe non-controlled substances via telehealth. For controlled substances, they will likely adhere to the current regulations, potentially requiring an in-person initial visit.

Important Considerations:

• State Laws Vary: While the DEA sets federal controlled substance rules, individual states also have their own medical board regulations regarding telehealth and prescribing. These can add further restrictions. Always check the laws in your specific state.
• Provider Discretion: Even if permitted by law, individual providers or telehealth platforms may choose not to prescribe controlled substances via telehealth due to their own policies or comfort levels.
• Pharmacy Discretion: Pharmacies can refuse to fill a prescription if they have concerns about its legitimacy, regardless of how it was prescribed.
• Future Rules: The DEA is still working on final, permanent regulations for telehealth prescribing of controlled substances. The situation could evolve again.

In summary, the era of easily accessible, fully online ADHD stimulant prescriptions for new patients has largely ended with the expiration of the PHE waiver, at least until the DEA finalizes new permanent rules. Existing patients have a temporary reprieve until December 31, 2024. For new patients, expect an in-person component to be required for stimulant medications.